BSX Stock Recent News
BSX LATEST HEADLINES
Boston Scientific (BSX) concluded the recent trading session at $102.36, signifying a +1.05% move from its prior day's close.
Boston Scientific's Neuromodulation unit witnesses 6.8% growth in the first quarter, fueled by strong gains in pain and brain therapy lines.
Boston Scientific offers steady growth with broader exposure, while Intuitive Surgical leads in robotics but faces margin and tariff headwinds.
Now is an opportune time to focus on income stocks like that offer value and stability amid market volatility. I focus on 2 Dividend Aristocrats that are attractively valued while supporting well-covered dividends. Both carry A/A+ rated balance sheets and have potential for strong total returns with a solid starting yield.
Boston Scientific (NYSE:BSX) has experienced a stock price increase of over 30% in the last twelve months, greatly exceeding the S&P 500's gain of 9%. This remarkable performance can be credited to the launch of new products, which have enhanced sales growth and widened profit margins.
The latest trading day saw Boston Scientific (BSX) settling at $99.74, representing a +1.2% change from its previous close.
Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors?
Boston Scientific's Q1 2025 Endoscopy sales jump 6%, powered by innovation in stents, clips and surgical tools for GI care.
Boston Scientific BSX, a prominent global player in cardiovascular technology, is well-positioned to capitalize on the robust expansion of the cardiovascular devices market. According to a MarketsandMarkets report, this market was valued at $72.83 billion in 2023 and is expected to witness a strong CAGR of 7.3% between 2024 and 2029.
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).